VTVT
vTv Therapeutics Inc - Ordinary Shares - Class A

14,741
Mkt Cap
$159.47M
Volume
46,127.00
52W High
$44.00
52W Low
$14.00
PE Ratio
-11.48
VTVT Fundamentals
Price
$38.16
Prev Close
$39.32
Open
$39.66
50D MA
$36.41
Beta
0.87
Avg. Volume
21,979.70
EPS (Annual)
-$3.20
P/B
2.13
Rev/Employee
$44,217.39
$45.22
Loading...
Loading...
News
all
press releases
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 61.2% in February
vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) saw a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 50,829 shares, an...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Recommendation of "Moderate Buy" from Analysts
vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has...
MarketBeat·6d ago
News Placeholder
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat.com...
MarketBeat·1mo ago
News Placeholder
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 62.3%
vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 27,101...
MarketBeat·1mo ago
News Placeholder
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, MarketBeat reports...
MarketBeat·2mo ago
News Placeholder
vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at TD Cowen
TD Cowen began coverage on vTv Therapeutics in a research report on Monday. They set a "buy" rating and a $67.00 price objective for the company...
MarketBeat·2mo ago
News Placeholder
This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
read more...
Benzinga·2mo ago
News Placeholder
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen
Wall Street Zen upgraded vTv Therapeutics to a "sell" rating in a report on Saturday...
MarketBeat·2mo ago
News Placeholder
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know
vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's What Happened
vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above 50 Day Moving Average - Here's Why...
MarketBeat·3mo ago
<
1
2
...
>

Latest VTVT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.